Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 21, 2003. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares and American Depositary Receipts (ADRs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity ownership changes rather than operational financial performance.
Material Changes
The filing details specific increases in shareholdings for the GlaxoSmithKline US Retirement Savings Plan and Director Dr. J.P. Garnier:
- US Retirement Savings Plan: On January 17, 2003, the fund's holdings increased from 18,237,538 to 18,263,970 Ordinary Share ADRs at an average price of $38.39.
- Dr. J.P. Garnier (Retirement Plan): Increased interest by 74 Ordinary Share ADRs at $38.39 per share on January 17, 2003.
- Dr. J.P. Garnier (Mid-Term Incentive Plan): Increased interest by 637.462 Ordinary Share ADRs at $50.45 per ADR on January 21, 2003, following the re-investment of dividends paid on January 3, 2003.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a routine disclosure of director share transactions.
Investor Verification Points
- Verify the total aggregate shareholding of Dr. J.P. Garnier across all plans to assess total exposure.
- Confirm the pricing discrepancy between the Retirement Plan ($38.39) and the Mid-Term Incentive Plan ($50.45) to understand the valuation basis for each transaction.
- Review the full 20-F annual report for comprehensive financial performance data, as this 6-K contains no operational metrics.